Sermorelin

Overview

Sermorelin (also written GHRH (1-29) or GRF 1-29; former brand names Geref and Geref Diagnostic) is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH). This 1-29 fragment is widely described as the shortest fully active fragment of GHRH: the smallest portion of the native hormone that retains essentially full ability to stimulate growth hormone (GH) release.

Unlike most peptides discussed on this site, sermorelin has a genuine regulatory history: it was approved by the U.S. Food and Drug Administration, first as a diagnostic agent and later as a treatment for growth hormone deficiency in children. However, the branded products were voluntarily discontinued in the United States around 2008 for commercial reasons, not because of any safety or effectiveness problem. As a result, there is currently no FDA-approved sermorelin product on the U.S. market, and the molecule is now encountered mainly through compounding pharmacies.

Like Tesamorelin and CJC-1295, sermorelin works by stimulating the body's own pituitary release of GH rather than supplying GH directly. It belongs to the same broad pharmacological family as the ghrelin-receptor agonist Ipamorelin, though those compounds differ in structure, duration, and regulatory standing.

Chemistry and structure

Sermorelin is a 29-amino-acid peptide with a C-terminal amide. Its sequence is identical to residues 1-29 of human GHRH, the N-terminal portion that carries the receptor-activating "message" of the full 44-residue hormone.

The native GHRH(1-29) sequence is rapidly degraded in plasma, principally by dipeptidyl peptidase-4 (DPP-4), which cleaves between the alanine at position 2 and the aspartate at position 3. This vulnerability is the reason sermorelin has such a short half-life, and it is also the reason later analogs (for example, the "modified GRF 1-29" / CJC-1295 family) introduce amino-acid substitutions or attachments specifically to slow this enzymatic breakdown. Sermorelin itself contains no such stabilizing modification; it is essentially the natural active fragment.

Mechanism of action

Sermorelin binds to the GHRH receptor (GHRHR) on the somatotroph cells of the anterior pituitary, mimicking the action of full-length endogenous GHRH. Receptor activation triggers the synthesis and pulsatile release of the body's own growth hormone. Circulating GH then acts on the liver and peripheral tissues, raising insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream growth and metabolic effects.

A defining feature of this mechanism is that it works through the body's existing regulatory axis rather than bypassing it. Because GH release is still subject to normal feedback (notably suppression by somatostatin and by IGF-1), sermorelin tends to preserve a pulsatile pattern of GH secretion rather than producing the sustained, supraphysiologic levels associated with injecting exogenous GH. This physiological character was one of the rationales for its historical diagnostic and pediatric use.

Because sermorelin acts at the pituitary level, it cannot, by itself, distinguish GH deficiency that originates in the hypothalamus from deficiency originating in the pituitary; a pituitary that responds to sermorelin demonstrates secretory capacity regardless of upstream hypothalamic status. This is a recognized limitation of GHRH-based diagnostic testing.

Clinical evidence and historical approval

Sermorelin is unusual among the peptides on this site in having been studied in controlled clinical trials in children and in having held formal regulatory approval.

Thorner et al., JCEM 1996 (Geref International Study Group). In a multicenter study of 110 prepubertal children with growth hormone deficiency, once-daily subcutaneous GHRH(1-29) (sermorelin, 30 micrograms/kg at bedtime) for one year increased height velocity from about 4.1 cm/year at baseline to roughly 8.0 cm/year at 6 months and 7.2 cm/year at 12 months, with appropriate bone maturation and no adverse metabolic signal. This trial supported the use of sermorelin to accelerate growth in GH-deficient children.

Kirk et al., Clinical Endocrinology 1994. In a smaller study of prepubertal children with idiopathic short stature, twice-daily subcutaneous GHRH(1-29)NH2 raised mean height velocity from about 4.8 cm/year to 7.2 cm/year over 12 months. The effect was reversible: children showed "catch-down" growth after stopping therapy, with velocity returning toward baseline, which shows that benefit depended on continued treatment.

Chen et al., Acta Paediatrica Suppl 1993. A comparative study in 60 GH-deficient children found that direct GH therapy outperformed GHRH(1-29)-NH2 for promoting growth (mean 6-month height velocities of roughly 14.6 cm/year for GH versus about 9.2-9.3 cm/year for the GHRH groups). Most patients receiving the GHRH analog developed anti-GHRH antibodies, which largely disappeared after treatment stopped.

Prakash & Goa, BioDrugs 1999 (review). This review summarized sermorelin's role both as a diagnostic agent (a single intravenous dose to test pituitary GH-secretory capacity, reportedly producing fewer false positives than some other provocative tests) and as a treatment (daily subcutaneous injection that significantly raised height velocity over 12 months in GH-deficient children). It noted that sermorelin's growth-promoting effect appeared somewhat less robust than direct GH therapy and described the therapeutic evidence as limited at the time.

Consider what this evidence does not cover. The controlled human data concern children with growth hormone deficiency or short stature and diagnostic testing of GH secretion. There is no comparable body of controlled evidence establishing sermorelin as a safe or effective treatment for "anti-aging," body composition, athletic performance, or general wellness in healthy adults, the contexts in which it is frequently marketed today.

Safety and risks

In the pediatric trials and diagnostic use that underpinned its approval, sermorelin was generally well tolerated. The most commonly reported adverse effects were local injection-site reactions (redness, pain, swelling, or itching). Other reported effects have included flushing, headache, dizziness, nausea, and a sensation of warmth. As noted above, repeated dosing in children was associated with the development of anti-GHRH antibodies in some studies, though these typically waned after treatment stopped.

Because sermorelin raises GH and IGF-1, the general cautions that apply to stimulating the GH/IGF-1 axis are relevant by analogy to other GH secretagogues:

• IGF-1 elevation: GH-axis stimulation increases IGF-1; sustained elevation is a theoretical concern with respect to abnormal tissue growth.
• Glucose metabolism: GH can affect insulin sensitivity and glucose handling.
• Malignancy and pituitary disease: Stimulating the GH axis is generally avoided in the setting of active malignancy or known pituitary/hypothalamic pathology.

Regulatory status

United States — approval history (now discontinued):

• December 28, 1990: FDA approval of Geref Diagnostic (sermorelin acetate injection, 0.05 mg base/amp; NDA 19-863) as a diagnostic agent to evaluate the pituitary's capacity to secrete growth hormone.
• 1997: FDA approval of Geref (sermorelin acetate injection, 0.5 mg and 1.0 mg base/vial; NDA 20-443) for the treatment of idiopathic growth hormone deficiency in children with growth failure.
• 2008: The manufacturer (EMD Serono) notified the FDA that both Geref formulations were being discontinued.
• June 18, 2009: The FDA's withdrawal of approval of the two NDAs became effective.
• 2013: The FDA published a Federal Register determination that the Geref products were not withdrawn from sale for reasons of safety or effectiveness — confirming that the exit from the market was a commercial/business decision.

Today (compounding): Because no FDA-approved sermorelin product is marketed, sermorelin in the United States is generally encountered as a compounded preparation (prepared by 503A or 503B compounding pharmacies) when prescribed by a clinician. Compounded sermorelin is not an FDA-approved finished drug, and its identity, potency, and quality depend on the compounding facility. It is not approved for anti-aging, weight loss, athletic, or general wellness use.

For diagnostic GH-secretion testing, sermorelin's former role has largely been superseded by other agents and testing strategies; for example, macimorelin (an orally active ghrelin-receptor agonist) was later approved as a diagnostic for adult growth hormone deficiency.

How it compares

Sermorelin is one of several compounds that raise the body's own GH, but none is a like-for-like substitute for another; they differ in mechanism, duration, and, importantly, regulatory status.

A few neutral, factual points:

• Sermorelin and Tesamorelin are both GHRH-based and both stimulate the GH axis, but tesamorelin is a stabilized GHRH(1-44) analog that currently holds FDA approval for a narrow HIV indication, whereas sermorelin's approved product is no longer marketed.
• CJC-1295 is essentially an engineered descendant of GHRH(1-29) designed to resist the DPP-4 cleavage that limits sermorelin's half-life; it has never been FDA-approved.
• Ipamorelin works through a different receptor (the ghrelin/GH-secretagogue receptor), so it is mechanistically distinct from the GHRH analogs even though it also increases GH; it is not FDA-approved.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Sermorelin's historical approvals were for supervised diagnostic and pediatric medical use; no FDA-approved sermorelin product is currently marketed. Nothing here should be interpreted as guidance to obtain or use sermorelin outside of an approved, supervised clinical context, and no dosing or sourcing information is provided.